2022
Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency
Shin JJ, Par-Young J, Unlu S, McNamara A, Park HJ, Shin MS, Gee RJ, Doyle H, Afinogenova Y, Zidan E, Kwah J, Russo A, Mamula M, Hsu FI, Catanzaro J, Racke M, Bucala R, Wilen C, Kang I. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency. Journal Of Clinical Immunology 2022, 42: 1137-1150. PMID: 35713752, PMCID: PMC9203263, DOI: 10.1007/s10875-022-01296-4.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCD8-Positive T-LymphocytesCommon Variable ImmunodeficiencyCOVID-19COVID-19 VaccinesHumansImmunity, CellularImmunoglobulin AImmunoglobulin GMRNA VaccinesPrimary Immunodeficiency DiseasesRNA, MessengerSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationVaccinesVaccines, SyntheticConceptsCommon variable immune deficiencyT cellsImmune responseIgG responsesCVID patientsMRNA vaccinesB cellsCoronavirus disease 2019 (COVID-19) mRNA vaccinesCOVID-19 mRNA vaccinesBaseline immune profileHistory of autoimmunityPrimary antibody deficiencyT cell responsesCellular immune responsesPoor immune responseVariable immune deficiencyMemory B cellsSARS-CoV-2 spike proteinBaseline IgGCVID diagnosisEM CD8Immunological predictorsPAD cohortSpecific CD4Immune profile
2021
Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer
Slovak RJ, Park HJ, Kamp WM, Ludwig JM, Kang I, Kim HS. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Scientific Reports 2021, 11: 6956. PMID: 33772035, PMCID: PMC7997991, DOI: 10.1038/s41598-021-85810-5.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDCD4-Positive T-LymphocytesCell Line, TumorCell ProliferationColorectal NeoplasmsCTLA-4 AntigenFemaleHepatitis A Virus Cellular Receptor 2Immune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingMaleMiceMice, Inbred BALB CMicrosatellite RepeatsProgrammed Cell Death 1 ReceptorSpleenT-Lymphocytes, CytotoxicConceptsDual checkpoint inhibitionPD-1 inhibitionColorectal cancerCheckpoint inhibitionPD-1Checkpoint inhibitorsT cellsImmune responseRobust anti-tumor immune responseAnti-PD-1 groupAnti-PD-1 antibodyAnti-tumor immune responseMicrosatellite stable colorectal cancerDual PD-1Majority of patientsDeficient mismatch repairStable colorectal cancerCTLA-4 inhibitionTumor growth rateHigh microsatellite instabilityPotential escape mechanismsCombination immunotherapyImmunosuppressive checkpointsTumoral infiltrationDual therapy
2020
Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
Kamp W, Park H, Slovak R, Ludwig J, Kang I, Kim H. Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Journal Of Clinical Oncology 2020, 38: 160-160. DOI: 10.1200/jco.2020.38.4_suppl.160.Peer-Reviewed Original ResearchDual immune checkpoint blockadeAnti-PD-1 antibodyColorectal cancerPD-1T cellsImmune responseMurine colorectal cancer cellsBALB/c miceDual checkpoint inhibitionExpression of TIM3Subcutaneous flank injectionNumber of CD8PD-1 inhibitionImmune checkpoint blockadeDeficient mismatch repairColorectal cancer cellsHigh microsatellite instabilitySignificant clinical impactPotential escape mechanismsCombination immunotherapyImmunosuppressive checkpointsCheckpoint inhibitorsMonotherapy groupCheckpoint blockadeMost patientsSystemic impact on tumor growth after combined immuno-thermal ablation in a murine model of colorectal cancer.
Slovak R, Park H, Kamp W, Ludwig J, Kang I, Kim H. Systemic impact on tumor growth after combined immuno-thermal ablation in a murine model of colorectal cancer. Journal Of Clinical Oncology 2020, 38: 198-198. DOI: 10.1200/jco.2020.38.4_suppl.198.Peer-Reviewed Original ResearchDual immune checkpoint blockadeTreatment days 0Target tumorTumor volumeDay 0Anti-cancer immune responseBALB/c miceAddition of immunotherapyImmune checkpoint blockadeTreatment day 2Colorectal cancer cellsInjection of antibodiesFull ablationCheckpoint blockadeColorectal cancerC miceSham injectionMean changeImmune responseMurine modelControl animalsCryoablationDay 2Tumor growthFlank injection
2017
Sex-specific regulation of immune responses by PPARs
Park H, Choi J. Sex-specific regulation of immune responses by PPARs. Experimental & Molecular Medicine 2017, 49: e364-e364. PMID: 28775365, PMCID: PMC5579504, DOI: 10.1038/emm.2017.102.Peer-Reviewed Original ResearchConceptsImmune responseT cellsEffector T cell responsesPeroxisome proliferator-activated receptor ligandsSex-specific immune responsesExperimental autoimmune encephalomyelitisEffector T cellsT cell responsesRole of PPART cell activationHost diseaseAutoimmune encephalomyelitisAutoimmune diseasesSex hormonesForeign antigensSex-specific differencesKnockout miceMetabolic diseasesImmune systemPPARReceptor ligandsInhibitory functionDiseaseSex-specific regulationSex differences
2015
Piceatannol inhibits effector T cell functions by suppressing TcR signaling
Kim D, Lee Y, Park H, Lee J, Kim H, Hwang J, Choi J. Piceatannol inhibits effector T cell functions by suppressing TcR signaling. International Immunopharmacology 2015, 25: 285-292. PMID: 25676533, DOI: 10.1016/j.intimp.2015.01.030.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDAntigens, Differentiation, T-LymphocyteCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell DifferentiationCytokinesFemaleInterleukin-2 Receptor alpha SubunitLectins, C-TypeMice, Inbred C57BLMitogen-Activated Protein KinasesPhosphorylationProtein Kinase InhibitorsReceptors, Antigen, T-CellSpleenStilbenesConceptsEffector T cell functionT cell functionT cellsPiceatannol treatmentT cell activation markers CD25Naïve CD4 T cellsRole of piceatannolCD4 T cellsActivation markers CD25Cell functionAdaptive immune responsesSplenic T cellsMetabolite of resveratrolMurine splenic T cellsInhibition of TCRActivated T cellsAnti-tumorigenesis activityT cell activationIL-17Th17 cellsCytokines IFNγC57BL/6 miceCytokine productionIL-2Immune response